Immunotherapy News and Research

Latest Immunotherapy News and Research

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced the presentation of interim data from a Phase 1B trial (PN001) evaluating MK-3475, an investigational anti-PD-1 immunotherapy, in patients with previously-treated non-small cell lung cancer (NSCLC). The data were presented today by Dr. Edward Garon, Director of Thoracic Oncology, Jonsson Comprehensive Cancer Center, University of California, Los Angeles, at the 15th World Conference on Lung Cancer in Sydney, Australia (Abstract #2416).

31 Oct 2013

Immune Design closes Series C financing totalling up to $49M

Immune Design, a biotechnology company focused on the development of novel immune-based therapies for cancer and other chronic conditions, today announced it has closed a Series C financing totalling up to $49 million.

30 Oct 2013

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

An experimental new cancer drug called MK-3475, which has shown dramatic promise for treating melanoma is also showing early potential as an effective treatment for patients with non-small cell lung cancer, the leading cause of cancer death of men and women worldwide.

30 Oct 2013

State-of-the-art HIV vaccine laboratory opens in Cape Town, South Africa

Fred Hutchinson Cancer Research Center tomorrow will celebrate the grand opening of a state-of-the-art HIV vaccine laboratory in Cape Town, South Africa.

24 Oct 2013

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

...

23 Oct 2013

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

Aduro BioTech, Inc. announced today that the Office of Orphan Products Development of the Food and Drug Administration has granted orphan drug designation for CRS-207, a novel immunotherapy, for the treatment of pancreatic cancer.

22 Oct 2013

Anergis reports immunology data from AllerT Phase IIb study for birch pollen allergy

Anergis, a company focusing on proprietary allergy vaccines, today reported immunology data from the Phase IIb study of its lead compound AllerT.

21 Oct 2013

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.

21 Oct 2013

Advaxis announces full exercise of over-allotment option granted to underwriters

Advaxis, Inc., a leader in developing the next generation of immunotherapies for cancer and infectious diseases, today announced the full exercise of the over-allotment option granted to the underwriters to purchase an additional 862,500 shares of its common stock and warrants to purchase an additional 431,250 shares (15% of the shares and warrants sold in this offering), at a public offering price of $4.00 per share and $0.001 per warrant, respectively, in connection with its previously announced underwritten public offering of 5,750,000 shares of common stock, and warrants to purchase up to an aggregate of 2,875,000 shares of common stock, bringing the total gross proceeds from the offering to approximately $26,500,000, before deducting underwriting discounts and commissions and other offering expenses payable by Advaxis, Inc.

19 Oct 2013

Genalyte Gets Grant From NCI To Develop Biomarker Panel For Cancer

...

18 Oct 2013

Genalyte receives NCI grant to develop biomarker panel to profile TAA autoantibodies

Genalyte, Inc., today announced that it has received a $1 million SBIR grant from the National Cancer Institute to develop a biomarker panel to profile tumor antigen-associated autoantibodies.

18 Oct 2013

Imaxio Sells Genomics Division To Hybrigenics

...

16 Oct 2013

CEL-SCI, Ergomed To Co-Develop Head And Neck Cancer Candidate As Potential HPV Treatment

...

16 Oct 2013

CEL-SCI, Ergomed To Co-Develop Head And Neck Cancer Candidate As Potential HPV Treatment

...

15 Oct 2013

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

House dust mite allergy is a surprisingly prevalent problem. Something like 27% of the U.S. population and 20% of the European population are what’s called skin-prick test positive for house dust mites, which is a test for sensitivity to allergens to find out if a person is likely to get that allergy.

15 Oct 2013

immatics biotechnologies closes €34 million Series D financing round

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced multi-peptide cancer vaccines that are active against cancer, today announced that it has closed a €34 million Series D financing round.

15 Oct 2013

Promising new type of cancer treatment to benefit more patients

More patients than ever stand to benefit from a promising new type of cancer treatment, after scientists compiled a library of molecules that can prime patients’ immune systems to fight a range of cancers including leukaemia, myeloma, lung cancer and skin cancer.

15 Oct 2013

Football-shaped artificial particles teach immune cells to recognize, destroy cancer cells

Researchers at Johns Hopkins have succeeded in making flattened, football-shaped artificial particles that impersonate immune cells. These football-shaped particles seem to be better than the typical basketball-shaped particles at teaching immune cells to recognize and destroy cancer cells in mice.

14 Oct 2013

Researchers identify genetic variants associated with Barrett's and esophageal cancer

An international consortium co-led by researchers at Fred Hutchinson Cancer Research Center and the QIMR Berghofer Medical Research Institute in Australia has identified four genetic variants associated with an increased risk of esophageal cancer and its precursor, a condition called Barrett's esophagus.

14 Oct 2013

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Cancer immunotherapy can successfully use the body's own immune system to kill tumor cells. But some current approaches to stimulate an antitumor immune response are short-lived, with limited clinical effectiveness. A new gene transfer strategy that introduces modified, immune-stimulating human stem cells is both feasible and effective for achieving persistent immunotherapy to treat leukemias and lymophomas, according to a study published in Human Gene Therapy, a peer-reviewed journal from Mary Ann Liebert, Inc., publishers.

11 Oct 2013

Immunotherapy News and Research

Latest Immunotherapy News and Research

Interim data from Phase 1B trial of an investigational anti-PD-1 immunotherapy in patients with previously-treated NSCLC announced by Merck

Immune Design closes Series C financing totalling up to $49M

Promising melanoma drug demonstrates potential for non-small cell lung cancer treatment

State-of-the-art HIV vaccine laboratory opens in Cape Town, South Africa

Imugene Acquiring Biolife, As Lead Pipeline Candidate Nears Phase II

FDA grants orphan drug designation to Aduro's CRS-207 for treatment of pancreatic cancer

Anergis reports immunology data from AllerT Phase IIb study for birch pollen allergy

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Advaxis announces full exercise of over-allotment option granted to underwriters

Genalyte Gets Grant From NCI To Develop Biomarker Panel For Cancer

Genalyte receives NCI grant to develop biomarker panel to profile TAA autoantibodies

Imaxio Sells Genomics Division To Hybrigenics

CEL-SCI, Ergomed To Co-Develop Head And Neck Cancer Candidate As Potential HPV Treatment

CEL-SCI, Ergomed To Co-Develop Head And Neck Cancer Candidate As Potential HPV Treatment

House dust mite allergy treatment: an interview with Steve Harris, CEO & Co-founder of Circassia

immatics biotechnologies closes €34 million Series D financing round

Promising new type of cancer treatment to benefit more patients

Football-shaped artificial particles teach immune cells to recognize, destroy cancer cells

Researchers identify genetic variants associated with Barrett's and esophageal cancer

New gene transfer strategy effective for achieving persistent immunotherapy to treat tumors

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Immunotherapy News and Research

Latest Immunotherapy News and Research

Exploring Strategies for Targeting Kinases in Innate Immunity eBook

CellVoyant's AI-Powered Vision for the Future of Cell Therapy

Scalable, Smart, and Accessible: The Future of Lab Automation

Healthy Beginnings, Hopeful Futures: A Conversation with WHO’s Dr. Allotey

Newsletters you may be interested in